20 Oct 2017

UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook

Read More
19 Oct 2017

By the time you finish reading this headline another person will have suffered a fragility fracture due to osteoporosis1

Read More
13 Oct 2017

Transparency notification The Capital Group Companies

Read More
21 Sep 2017

UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives EU approval for paediatric use

Read More
15 Sep 2017

New indication for BRIVIACT® (brivaracetam): UCB’s newest antiepileptic drug approved by FDA as monotherapy treatment of partial-onset seizures in adults

Read More
14 Sep 2017

New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress

Read More
11 Sep 2017

EVENITYTM (romosozumab) ARCH Study Results Published in the New England Journal of Medicine

Read More
7 Sep 2017

UCB highlights latest EVENITY™ (romosozumab) research at the American Society for Bone and Mineral Research Annual Meeting

Read More
23 Aug 2017

Transparency notification Wellington 

Read More
2 Aug 2017

Transparency notification The Capital Group Companies

Read More
Subscribe to